Share on LinkedInShare on LinkedIn

ARTICLE · 14 APRIL 2020

Spotlight On Upcoming Oral Arguments – April 2020

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Lipoline initiated an interference proceeding on Clarus's patent under 35 U.S.C. § 135(a). Lipoline argued to the Patent Trial and Appeal Board ("PTAB")...

United StatesIntellectual Property

Clarus Therapeutics, Inc. v. Lipoline, Inc., No. 19-1566, Courtroom 402 (telephonic argument)

Lipoline initiated an interference proceeding on Clarus's patent under 35 U.S.C. § 135(a). Lipoline argued to the Patent Trial and Appeal Board (“PTAB”) that Clarus's patent cannot claim a priority date to a provisional application, because the provisional application did not provide sufficient written description support for the claimed formulation. The PTAB granted Lipoline's motion on the priority date. Then, Lipoline convinced the PTAB that its own invention date preceded the patent's priority date. As a result, the PTAB revoked Clarus's patent.

On appeal, Clarus argues that the provisional application provides at least one anticipatory embodiment of the claim, allowing a person of ordinary skill in the art (“POSA”) to recognize that the inventor invented what is claimed. More specifically, Clarus argues that to provide support for the claimed negative limitation at

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from